Background {#Sec1}
==========

Interstitial lung disease (ILD) is caused by various etiologies including collagen vascular disease, drug induced and inhalation exposure. Patients with ILD often have collagen vascular disease-related autoantibodies even when they do not fulfill the diagnostic criteria for any collagen vascular diseases \[[@CR1]\]. In 2015, the "European Respiratory Society (ERS)/American Thoracic Society (ATS) Task Force on Undifferentiated Forms of Connective Tissue Disease-associated Interstitial Lung Disease" proposes the term "interstitial pneumonia with autoimmune features" (IPAF) and offers classification criteria organized around the presence of a combination of features from three domains: a clinical domain, a serologic domain and a morphologic domain \[[@CR2]\]. Recent report showed autoantibodies against aminoacyl-tRNA synthetase (ARS) have been found to be highly specific for myositis and to associate with complicating ILD, arthritis, Raynaud's phenomenon, mechanic's hand and fever. Ten anti-ARS antibodies have been identified: anti-Jo-1, EJ, PL-7, PL-12, OJ, KS, Zo, SC, JS and YRS antibodies \[[@CR3], [@CR4]\].

Anti-ARS antibodies are positive in 20%--35% of patients with polymyositis/dermatomyositis (PM/DM) \[[@CR3], [@CR5]\]. Among patients with PM/DM, anti-Jo-1 antibody is the most common (15%--30%) while others are seen in less than 10% \[[@CR6]\]. Although, anti-EJ antibody, which is against glycyl-tRNA synthetase \[[@CR7]\], is generally less common than anti-Jo-1 antibody, it has a higher prevalence than anti-Jo-1 antibody in some case series of patients with ILD positive of anti-ARS antibodies (ARS-ILD) \[[@CR8], [@CR9]\]. Meanwhile, over 90% of patients with positive-anti-ARS antibodies show ILD complications \[[@CR10]\].

On computed tomography (CT), patients with ARS-ILD often have radiologically traction bronchiectasis, consolidation and volume loss predominantly in the lower lung zones \[[@CR9], [@CR11], [@CR12]\]. Histopathological patterns are reported as nonspecific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), acute lung injury (ALI) or diffuse alveolar damage (DAD) \[[@CR9], [@CR11]--[@CR13]\]. Although clinical course of treatment response to ARS-ILD is reportedly good, relapses are frequent \[[@CR14]\].

However, there are only a few reports describing the clinical features of patients with ILD with positive-anti-EJ antibody (EJ-ILD) \[[@CR15], [@CR16]\]. The aim of this retrospective study was to define the clinical, radiological and pathological features of patients with EJ-ILD with long-term follow-up.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

We retrospectively analyzed the medical records of 12 consecutive patients with EJ-ILD who underwent surgical lung biopsy at Kanagawa Cardiovascular and Respiratory Center between March 2005 and April 2013 and were subsequently followed up for over one year. Anti-ARS antibodies were detected with an immunoprecipitation assay at Tokai University School of Medicine as previously described method \[[@CR17]\].

Clinical information {#Sec4}
--------------------

We obtained the clinical presentations, physical findings, laboratory findings and pulmonary function tests at the initial visit from patients' medical records. The diagnosis of PM/DM was based on Bohan and Peter's criteria \[[@CR18]\]. Patients satisfying at least two of the five of the criteria were diagnosed with PM/DM. IPAF and anti-synthetase syndrome were diagnosed according to each proposed criteria \[[@CR2], [@CR19]\]. The onset of EJ-ILD was divided into two types according to the time from the initial symptoms to the initial hospital visit: 1) within three months (acute onset) and 2) over three months (chronic onset). The pattern of ILD onset in PM/DM patients was divided into three types: 1) PM/DM was diagnosed at least three months earlier than ILD (PM/DM-preceding type), 2) ILD was diagnosed at least three months earlier than PM/DM (ILD-preceding type), and 3) both occurred within three months (simultaneous type) \[[@CR14]\].

Radiological analysis {#Sec5}
---------------------

CT images before biopsy were obtained from all the 12 patients. All images were reviewed independently by two experienced radiologists without any prior knowledge of the clinical and pathological information.

To determine the distribution and extent of parenchymal abnormalities, each lung was divided into three zones of upper, middle and lower at the level of the carina and the left inferior pulmonary vein. The following high resolution CT (HRCT) findings were coded as present or absent in each zone: reticulation, ground-glass opacity, consolidation, bronchovascular thickening, traction bronchiectasis, honeycombing, volume loss and emphysema. Radiological assessment was based on those from previous studies \[[@CR9], [@CR20]\]. Disagreements between the two radiologists were resolved by consensus.

Pathological analysis {#Sec6}
---------------------

Biopsy was performed in all patients. Multiple specimens mainly from the upper and lower lobes were obtained from 11 of 12 patients. All the specimens were stained with hematoxylin-eosin and Elastica van Gieson and were reviewed independently by two experienced lung pathologists who were not aware of the clinical and radiological findings. Pathological patterns were diagnosed according to the 2002 and 2013 ATS/ERS consensus classification of the idiopathic interstitial pneumonias and 2008 ATS project for idiopathic NSIP \[[@CR21], [@CR22]\].

The intensity and extent of the following pathological features were semi-quantitatively graded as absent, mild, moderate or severe: pleural fibrosis, pleuritis, lymphoid follicles with germinal center, organizing pneumonia, alveolar epithelial injury, interstitial cellular infiltration, alveolar wall fibrosis, microscopic honeycombing, fibroblastic focus and collapse. Pathological assessment was based on those from previous studies \[[@CR13], [@CR23], [@CR24]\].

Disagreements between the two pathologists were discussed until consensus was reached.

Clinical course and treatment response {#Sec7}
--------------------------------------

The clinical course and treatment response of EJ-ILD was evaluated on the basis of the degree of changes in both chest images and pulmonary functions. Two radiologists evaluated the chest radiograph and/or HRCT. We graded the changes in pulmonary functions according to the 2000 ATS/ERS consensus statement for idiopathic pulmonary fibrosis (Table [1](#Tab1){ref-type="table"}) \[[@CR25]\]. In addition, the pattern of disease behavior was divided into the following five types: 1) reversible and selflimited, 2) reversible disease with risk of progression, 3) stable with residual disease, 4) progressive, irreversible disease with potential for stabilization, and 5) progressive, irreversible disease despite therapy \[[@CR22]\].Table 1Definition of the initial response to treatmentEvaluation of pulmonary function test^a^ImprovedStableDeterioratedEvaluation of imagesImprovedImprovedImprovedDeterioratedStableImprovedStableDeterioratedDeterioratedImprovedDeterioratedDeteriorated^a^"Improved" meant at least 10% increase in forced vital capacity % predicted (%FVC) or at least 15% increase in diffusing capacity of the lung for carbon monoxide % predicted (%DL~CO~). Stable was defined as within 10% change of %FVC and within 15% change of %DL~CO~. "Deteriorated" meant over 10% decrease in %FVC or over 15% decrease in %DL~CO~.

The initial response was assessed within six months after the initiation of treatment. After the initial evaluation, we assessed all chest radiographs and pulmonary functions until the end of the follow-up period. The relapse of ILD meant that the patients with deterioration needed to reinforced therapy for ILD.

Results {#Sec8}
=======

Clinical and laboratory findings of EJ-ILD {#Sec9}
------------------------------------------

The summary of the clinical characteristics of the 12 patients is listed in Table [2](#Tab2){ref-type="table"}. The patients included five males and seven females with median age of 62 years (range, 47--75 years) at the initial visit. Eight patients presented acute onset.Table 2Clinical characteristics and diagnosis of 12 patientsClinical characteristics*n* = 12 Male/female5/7 Age at initial visit \[years\]62 (47--75) Acute onset/chronic onset8/4 Smoking status (current or former/never smoker)6/6Serological findings (reference value)*n* = 12 CK \[U/L\] (62--287)140 (17--672) LDH \[U/L\] (70--139)252 (212--337) ESR \[mm/h\] (2--10)38 (17--116) CRP \[mg/dl\] (0--0.1)0.63 (0.03--1.79) KL-6 \[U/ml\] (0--500)991 (514--3208) SP-D \[ng/ml\] (0--110)232.3 (56.1--723.1) PaO~2~ \[Torr\] (74--108)71.5 (53.0--84.5)Pulmonary functions*n* = 11 FVC % predicted \[%\]71.5 (42.4--86.1) DL~CO~ % predicted \[%\]66.1 (56.0--112.2)Data are presented as n, or median (range)*CK*: Creatine kinase, *LDH*: Lactate dehydrogenase, *ESR*: Erythrocyte sedimentation rate, *CRP*: C-reactive protein, *KL-6*: Klebs von den lungen-6, *SP-D*: Surfactant protein D, *PaO* ~*2*~: Arterial oxygen pressure, *FVC*: Forced vital capacity, *DL* ~*CO*~: Diffusion capacity for carbon monoxide

At the disease onset, extra-pulmonary symptoms were observed in only five patients, whereas all patients presented pulmonary symptoms. Only one patient was suffering from muscle weakness. Among six patients diagnosed with IPAF and anti-synthetase syndrome, no patient had skin involvement, and only one patient presented articular symptoms. Two patients have not had extra-pulmonary symptoms during entire follow-up period (Table [3](#Tab3){ref-type="table"}). Palmar telangiectasia was not assessed in all patients.Table 3Clinical symptoms and physical findings related to IPAF and anti-synthetase syndromePatient numberDiagnosisCoughDyspneaMechanic's hand, Gottron's signHeliotrope rashRaynaud's phenomenonArticular involvement^a^Unexplained digital oedemaUnexplained feverMuscular involvement^b^Distal digital tip ulcerationCK level1IPAF/ASS+\-\-\-\-\-\-\-\--2182IPAF/ASS++\-\--+\-\-\--1363IPAF/ASS+\-\-\-\-\-\-\-\--504PM^I^+\-\-\--+^c^\--+^c^-346^E^5IPAF/ASS++\-\-\-\--+^c^+^c^-516DM^I^+-+-+^c^\--+^c^\--1437IPAF/ASS++\-\-\-\--+^c^+^c^-178PM^I^+-+^c^-+^c^+^c^+^c^\-\--513^E^9DM^I^-++^c^-+^c^+^c^\--+^c^-13710IPAF/ASS++\-\-\-\--++^c^-2211PM^I^++\-\--++-+^c^-23012PM^S^++\-\-\-\--++-672^Ea^inflammatory arthritis, or polyarticular morning joint stiffness \> 60mins, ^b^proximal muscular weakness, or myalgia, *CK*: creatine kinase, *IPAF*: interstitial pneumonia with autoimmune features, *ASS*: anti-synthetase syndrome, *PM*: polymyositis, *DM*: dermatomyositis, *I*: interstitial lung disease preceded PM/DM, *S*: simultaneous onset of PM and interstitial lung disease, ^c^symptoms occurred during follow up, *E*: The CK level is greater than reference value

Creatine kinase levels were elevated in three patients and lactate dehydrogenase levels were elevated in eight, while all patients presented with the elevation of erythrocyte sedimentation rate, C-reactive protein, Klebs von den Lungen-6 and surfactant protein-D levels. Electromyography, muscle biopsy and magnetic resonance imagings of muscle were performed in only two DM patients.

Specific autoantibodies other than anti-EJ antibody were found in only one patient who had anti-SSA antibody at the initial visit and was diagnosed with Sjögren's syndrome 20 months after the diagnosis of EJ-ILD. Other patients had neither other autoantibodies nor the diagnosis of any other collagen vascular diseases except for PM/DM.

Six patients were diagnosed with PM/DM during the disease course and five of them were of the ILD-preceding type. Others were all diagnosed with idiopathic interstitial pneumonia and satisfied with the proposed criteria of both IPAF and anti-synthetase syndrome.

Radiological findings {#Sec10}
---------------------

The HRCT findings are described in Table [4](#Tab4){ref-type="table"}. All findings were observed in both lobes. All but one patient presented with reticulation and ground-glass opacity in all lobes. On the other hand, volume loss, bronchovascular thickening, traction bronchiectasis and consolidation were not common in the upper zone, but were predominant in the middle or lower zones in almost all patients. Consolidation was observed along the bronchus from the middle to the subpleural area. Bronchiectasis was noted inside the consolidation, which encompassed the lung architecture. Reticulation and ground-glass opacity were distributed around the consolidation. Typical HRCT images are shown in Fig. [1](#Fig1){ref-type="fig"}.Table 4HRCT findings of 12 patientsFindingsZonesUpperMiddleLowerReticulation111212Ground-glass opacity111212Volume loss2912Bronchovascular thickening11012Traction bronchiectasis51111Consolidation41111Honeycombing114Emphysema411Upper: between apex and carina, Middle: between carina and left inferior pulmonary vein, Lower: between inferior pulmonary vein and diaphragm Fig. 1HRCT images of patient \#9 (76-years-old female, pathologically cellular NSIP). **a** The coronal image of the high-resolution computed tomography (HRCT) showed bilateral volume loss and infiltration of lower lung field. **b**-**d** Transverse images of the HRCT. Consolidation was observed from middle area to the subpleural area. Traction bronchiectasis was noted inside of consolidation. Reticulation and ground-glass opacity were distributed around consolidation

Pathological findings {#Sec11}
---------------------

The median interval between the date of HRCT and biopsy was 28 days (range, 1--85 days). Four patients were pathologically diagnosed with cellular NSIP (c-NSIP), five were with fibrosing NSIP (f-NSIP), and three were with unclassifiable interstitial pneumonia. Organizing pneumonia, alveolar epithelial injury, interstitial cellular infiltration, pleural fibrosis and collapse with moderate or severe grade were observed in more than half of the patients (Table [5](#Tab5){ref-type="table"}). Especially organizing pneumonia and alveolar epithelial injury with moderate or severe grade were observed in two of four patients with c-NSIP and in four of five f-NSIP patients. Collapse was observed with moderate grade in one of four patients with c-NSIP and with moderate or severe grade in four of five with f-NSIP. Acute inflammatory findings such as organizing pneumonia, alveolar epithelial injury and interstitial cellular infiltration surrounded by collapse with few hyaline membrane were more prominent in unclassifiable interstitial pneumonia than in c-NSIP or f-NSIP. Organizing pneumonia, alveolar epithelial injury and collapse did not show diffuse but rather focal distribution. On the other hand, interstitial cellular infiltration and pleural fibrosis were diffuse. Typical pathological images are shown in Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}.Table 5Pathological diagnosis and findingsDiagnosis*n* = 12 cellular-NSIP4 fibrosing-NSIP5 unclassifiable interstitial pneumonia3Findingsabsentmildmoderatesevere Organizing pneumonia1074 Alveolar epithelial injury1182 Interstitial cellular infiltration0453 Pleural fibrosis0480 Collapse1461 Alveolar wall fibrosis3441 Pleuritis2910 Lymphoid follicles with germinal centers6600 Fibroblastic focus8220 Microscopic honeycombing10200Organizing pneumonia involved less than 20% of the overall biopsy specimen when the diagnosis was NSIP \[[@CR21]\]. Alveolar epithelial injury was defined as obscured border between alveolar septum and alveolar lumina with alveolar epithelial shedding, intra-alveolar cellular infiltration and membranous organization of the alveolar ducts and alveolar sac which meant focal acute lung injury. Collapse meant atelectatic alveoli with intra-alveolar fibrosis and agglutination of alveoli \[[@CR35]\].*NSIP*: nonspecific interstitial pneumonia Fig. 2Histopathology of surgical lung biopsies of patient \#10 (cellular NSIP, 62-years-old female, right S9). **a** Low power view of the specimen showed panlobular and homogeneous pattern including interstitial cellular infiltration and organization located in airspace or alveolar septa. **b**, **c** High power view of an area of a square of (**a**) revealed focal membranous organization (*arrows*) observed in the alveolar duct. Ill-defined border between the alveolar septa and alveolar lumina was seen. Staining: (**a**, **b**) Hematoxylin and eosin stain, (**c**) Elastica van Gieson stein, Magnification: (**a**) 1×, (**b**, **c**) 10× Fig. 3Histopathology of surgical lung biopsies of patient \#6 (fibrosing NSIP, 72-years-old female, left S9). **a**, **b** Uniform fibrosis of the same age was observed diffusely in alveolar septa. Collapse was observed partially (*square*). **c** A higher magnification of an area of a square of (**b**) showing intraluminal and mural incorporation fibrosis and condensed elastic fiber of the alveolar walls. Staining: (**a**) Hematoxylin and eosin stain, (**b**, **c**) Elastica van Gieson stein, Magnification: (**a**, **b**) 4×, (**c**) 10× Fig. 4Histopathology of surgical lung biopsies of patient \#3 (unclassifiable interstitial pneumonia, 60-years-old male, right S2). The specimen showed mixed fibrosing NSIP pattern and marked collapse with slight inflammatory cell infiltration. **a**, **b** Collapse with obliterative intraalveolar fibrosis and disrupted alveolar elastic fibers were observed in the *square*. **c** Fragmented elastic fibers of the alveolar walls were seen in a higher magnification of an area of a *square* of (**b**). Staining: (**a**) Hematoxylin and eosin stain, (**b**, **c**) Elastica van Gieson stein, Magnification: (**a**, **b**) 4×, (**c**) 10×

Organizing pneumonia and alveolar epithelial injury with moderate or severe grade were observed not only in patients with acute onset but also in those with chronic onset (Table [6](#Tab6){ref-type="table"}).Table 6Number of patients of each pathological finding with moderate or severe gradeFindingsacute onset (*n* = 8)chronic onset (*n* = 4)Organizing pneumonia83Alveolar epithelial injury64Interstitial cellular infiltration62Pleural fibrosis53Collapse34Alveolar wall fibrosis23Pleuritis01Lymphoid follicles with germinal centers00Fibroblastic focus02Microscopic honeycombing00

Clinical course and treatment response {#Sec12}
--------------------------------------

Details on the clinical courses and therapy of the 12 patients are shown in Table [7](#Tab7){ref-type="table"}. Seven patients were treated with combination therapy of corticosteroid and immunosuppressant as the initial treatment while five were given corticosteroid monotherapy. The initial dose of corticosteroid was 0.5 mg/kg/day of prednisone in 11 patients. The median time of prednisone dose tapering to 10 mg/day was 91 days (range, 60--132 days).Table 7The clinical courses and therapy of the 12 patientsPatient numberResponse to initial therapyDisease onsetDiagnosisPathological diagnosisInitial therapyObservation period (months)Period from initial therapy to relapse (months)Therapy at relapse^a^PrognosisDisease behavior1improvedacuteIIPc-NSIPPDN29\--aliveA2improvedacuteIIPunclassifiable IPPDN + CyA27\--aliveA3improvedacuteIIPunclassifiable IPPDN + TAC90\--aliveA4improvedchronicPMf-NSIPLow-PDN72\--aliveA5improvedchronicIIPc-NSIPPDN + TAC76\--aliveA6^SS^improvedchronicDMf-NSIPPDN + TAC19\--aliveA7relapsedacuteIIPf-NSIPPDN9429PDNaliveB8relapsedacutePMf-NSIPPDN^c^8261PDNaliveB9relapsedacuteDMc-NSIPPDN^c^708PDNaliveB10relapsedacuteIIPc-NSIPPDN^c^ + CyA11546PDN + CyAaliveB11relapsedchronicPMf-NSIPPDN + AZA10478PDNaliveB12deterioratedacutePM^b^unclassifiable IPPDN + CyA17\--deadC^a﻿^Patients have received these therapies until ILD relapsed., *SS*: Sjögren's syndrome, *IIP*: idiopathic interstitial pneumonia, *PM*: polymyositis, *DM*: dermatomyositis, ^b^simultaneous onset of PM and interstitial lung disease, *c-NSIP*: cellular nonspecific interstitial pneumonia, *f-NSIP*: fibrosing nonspecific interstitial pneumonia, *IP*: interstitial pneumonia, *PDN*: 0.5 mg/kg/day of prednisone, *CyA*: cyclosporine A, *TAC*: tacrolimus, *Low-PDN*: 0.2 mg/kg/day of prednisone, ^c﻿^started with methylprednisone pulse therapy (500 mg/body), *AZA*: azathioprine, A: progressive, irreversible disease with potential for stabilization, B: reversible disease with risk of progression, C: progressive, irreversible disease despite therapy

The initial response was evaluated as improved in 11 of 12 patients. Radiological findings improved in 11 of 12 patients. Representative images of chest radiograph are shown in Fig. [5](#Fig5){ref-type="fig"}, indicating the apparent lung volume recovery. Pulmonary function, evaluated in 10 patients, improved or stabilized in nine patients. Forced vital capacity % predicted (%FVC) and/or diffusing capacity of the lung for carbon monoxide % predicted (%DL~CO~) increased immediately after the initial treatment and remained almost stable between the initial evaluation period (Fig. [6](#Fig6){ref-type="fig"}). On disease behavior, the type of reversible disease with risk of progression were six patients, progressive and irreversible disease with potential for stabilization were five patients, and progressive and irreversible disease despite therapy were one patient. Patient \#12 was the only patient who did not respond to the treatment and died during the follow-up period.Fig. 5Changes of chest radiographs of patient \#11. **a** The initial chest radiograph before treatment showed infiltration and volume loss of lower lung field. **b** After four months from the initiation of treatment, consolidation and volume loss improved. **c** However they arose again at the time of relapse. **d** At the end of follow-up, treatment improved infiltration and volume Fig. 6Changes of pulmonary functions of 10 patients during initial evaluation period. Pulmonary function improved or was stable in nine patients. **a** Line graph of forced vital capacity % predicted. **b** Line graph of diffusing capacity of the lung for carbon monoxide % predicted

The median follow-up time was 74 months (range, 17--115 months). ILD relapsed in five of the 11 improved patients after a median of 46 months (range, 8--78 months) from treatment initiation. Among the five relapsed patients, four were on prednisone monotherapy and four presented with acute onset of the disease. There were few differences in the changes on chest radiograph and pulmonary function test between the relapsed patients and non-relapsed patients until relapse. However, upon relapse, the loss of lung volume was clearly recognized in chest radiograph, and both %FVC and %DL~CO~ significantly decreased. The addition of immunosuppressant and/or the increase of the dose of corticosteroid reduced the abnormal shadow and prevented deterioration of %FVC and %DL~CO~ (Fig. [7](#Fig7){ref-type="fig"}). On the other hand, four of the six patients without relapse had continuously been on combination therapy of corticosteroid and immunosuppressant.Fig. 7Changes of pulmonary functions of 10 patients during whole follow up period. Four patients deteriorated with corticosteroid monotherapy. **a** Line graph of forced vital capacity % predicted. **b** Line graph of diffusing capacity of the lung for carbon monoxide % predicted

Discussion {#Sec13}
==========

We retrospectively evaluated the clinical, radiological, pathological features and long-term clinical courses of 12 patients with EJ-ILD who underwent surgical lung biopsy. We have shown that patients with EJ-ILD had often acute onset of ILD with lower-lung predominant shadows with volume loss on HRCT, pathologically NSIP or unclassifiable interstitial pneumonia with acute inflammatory findings, and good response for initial steroid therapy, although relapse was frequent among the patients with corticosteroid monotherapy. In most patients with EJ-ILD clinical disease behavior was reversible or progressive and irreversible disease. Although anti-EJ antibodies correlated well with ILD, there are a few reports which describe the clinical, radiological and pathological findings of EJ-ILD and no reports describe any detailed clinical courses \[[@CR16], [@CR26]\]. To our knowledge, this is the first study to describe the detailed clinical features of biopsy-proven EJ-ILD with long-term follow-up period.

The onset of EJ-ILD was often acute in the present study. EJ-ILD progressed within three months in previous literature \[[@CR15], [@CR16]\]. Fifty to 70% of patients with anti-ARS antibodies other than anti-EJ antibody reportedly presented with chronic onset of ILD \[[@CR12], [@CR13], [@CR27]--[@CR29]\]. This suggests that onset of the disease varies among ARS-ILD, depending on the type of specific antibody.

Fifty percent of patients in this cohort were ultimately diagnosed with PM/DM, which was consistent with the previous report \[[@CR8], [@CR10]\]. However, our study showed that five of six PM/DM patients had ILD-preceding type, whereas only 30%--35% of patients with anti-ARS antibodies were reportedly ILD-preceding disease \[[@CR12], [@CR14], [@CR17], [@CR28]\].

Regarding to IPAF and anti-synthetase syndrome, almost no patient presented physical symptoms at initial visit. However, a half of them developed muscular symptoms and fever during follow-up period. This result is also compatible with the previous report \[[@CR10]\]. These suggest that it is difficult to distinguish anti-synthetase syndrome from IPAF at initial visit and pulmonary symptoms precede in some patients with anti-EJ antibody before developing anti-synthetase syndrome or PM/DM.

The HRCT findings were basically compatible with those of previous reports on ARS-ILD and ILD associated with PM/DM \[[@CR9], [@CR20], [@CR30]\]. Our study revealed consolidation and volume loss along the bronchovascular bundle predominantly in the middle and lower lung zones. These findings were similar to the radiological NSIP pattern \[[@CR21]\]. In some cases, changes in lung volume on chest radiograph correlated well with lung function and disease condition. Chest radiograph may be an adjunct indicator when chest CT is unavailable.

Pathologically unclassifiable interstitial pneumonia and NSIP were observed in our study although recent reports showed that the histopathological patterns of ARS-ILD were NSIP, UIP, ALI and DAD \[[@CR11], [@CR13], [@CR15], [@CR16]\]. Acute inflammatory findings have not been shown in ARS-ILD patients with chronic onset in previous literature \[[@CR13], [@CR15], [@CR16]\]. We here showed that acute inflammatory findings focally distributed with few hyaline membrane were observed not only in acute onset but also in chronic onset. In this point, our results support the recent reports. The pathological diagnosis of EJ-ILD may not match but resemble ALI and DAD because these were reported as indicating the diffuse and uniform widespread involvement of the pulmonary parenchyma and the pulmonary lobule with hyaline membrane \[[@CR15], [@CR16], [@CR31], [@CR32]\]. Moreover, the high prevalence of acute inflammatory findings and ILD distribution seem to suggest very similar type ILD as in other anti-synthetase antibodies. However, we cannot reliably draw a conclusion because of a small cohort size.

In this study, the initial treatment response of EJ-ILD and the rate of relapse were similar to those previously reported for ARS-ILD \[[@CR14]\]. Although the initial treatment for EJ-ILD was effective for most of the patients, ILD relapsed in nearly half of them. These findings suggest that the patients with EJ-ILD may have the potential high risk of disease progression. We found that those with relapse presented with NSIP, often on acute onset and were on corticosteroid monotherapy in this cohort, whereas the rate of relapse of ILD was lower in patients on combination therapy. To date, it has also been shown that in ARS-ILD the corticosteroid dose reduction might relate to the relapse \[[@CR12], [@CR14]\], and combination therapy of corticosteroid and tacrolimus was effective \[[@CR33]\]. The combination therapy was also recommended to treat ILD related to PM/DM \[[@CR34]\]. These suggest that combination therapy of corticosteroid and immunosuppressant may be preferable to corticosteroid monotherapy especially in case of acute-onset ILD.

This study has several limitations. First, it was a retrospective study with a small sample size. Second, since this study was performed in a specialized single-center for the respiratory diseases, there might be a selection bias for the diagnosis of PM/DM at the initial visit. However, in fact, all patients except patient \#12 had muscle weakness at the initial visit.

Conclusions {#Sec14}
===========

We delineated the long-term clinical characteristics of EJ-ILD. Because of the diversity of the clinical course, combination therapy of corticosteroid and immunosuppressant should be argued on a case-by-case basis to prevent relapse of EJ-ILD. We need to conduct long-term observation to assess clinical behavior and prevent complications of EJ-ILD.
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